Biomedical subjects

I Cavaco

Publications and source records attributed to I Cavaco.

3 recordsLinked to original sources

PubMed2006

Pharmacogenetics of cytochromes P450 in tropical medicine.

Drug response is affected by genetic and non-genetic factors, such as dietary compounds, sex, disease status and multiple drug therapy. Inherited determinants of drug disposition remain, however, the major cause of inter-individual differences due to pharmacogenetic polymorphism in drug metabolizing enzymes and transporters, or drug targets. Differences on ethnicity may have a profound impact on drug clearance, affecting the safety, efficacy and dosing regimen. In the context of tropical regions, the situation may be even more serious due to endemic infectious diseases and multiple drug therapy, which may affect drug clearance. In this review, we focus on the pharmacogenetics of the Cytochrome P450 superfamily, responsible for the highest contribution for variability among drug metabolizing enzymes, among ethnic groups from tropical settings.

Cytochrome P-450 Enzyme System↗

PubMed2005

CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

OBJECTIVE: The determination of the prevalence of the CYP2C8 main alleles in a typical set of malaria patients in Zanzibar, as these patients represent a typical population exposed to amodiaquine, an antimalarial mainly metabolized by CYP2C8. Also, to determine for the first time the frequencies of CYP2C8 alleles in native African populations. METHODS: Polymerase chain reaction-restriction fragment polymorphism for the identification of CYP2C8*1, CYP2C8*2, CYP2C8*3 and CYP2C8*4 on a random population of 165 unrelated malaria patients. RESULTS: The allele frequencies found were: CYP2C8*1 (wild type, 83.4%), CYP2C8*2 (13.9%), CYP2C8*3 (2.1%) and CYP2C8*4 (0.6%). In terms of genotypes, 70.4% of the patients showed the CYP2C8*1/ CYP2C8*1 genotypes, while heterozygous between the wild type and other minor alleles were seen in 26.0%. Finally, 3.6% of the patients were homozygous for slow metabolizer alleles. The frequencies observed are equivalent to those documented for African-Americans. CONCLUSIONS: CYP2C8 non-wild type alleles have a significant prevalence in the East African population studied. The consequent frequency of 3.6% of patients homozygous for slow metabolizer alleles represent a significant fraction of the population potentially in higher risk of adverse effects due to a less efficient metabolism of amodiaquine. As approximately 10(6) first-line treatments are currently performed in Zanzibar per year, this represents a non-negligible absolute number of amodiaquine exposures. This information constitutes a background for the pharmacovigilance programs presently being employed in Zanzibar.

Alleles↗

PubMed2000

Oxovanadium(IV) complexes with aromatic aldehydes.

The synthesis, structure and spectroscopic properties of complexes with the formula [V(IV)O(dsal)2(H2O)], where Hdsal = salicylaldehyde, o-vanillin and 3-ethoxysalicylaldehyde, are presented. The crystal and molecular structures of [V(IV)O(o-van)2(H2O)] (1) (o-Hvan = o-vanillin = 3-methoxysalicylaldehyde) is studied by single-crystal X-ray diffraction. Each molecule exhibits an octahedral geometry with the two o-van ligands coordinated cis to the V(IV)O2+ group. 1 is the first example of a structurally characterized vanadium complex involving O(aldehyde) as the donor atom and this enables a comparison between the bonding characteristics and the contributions of O(aldehyde), O(amide), O(carboxylate) and O(ketone) (in acetylacetone) to the parallel hyperfine coupling constant in VOL2 complexes.

Aldehydes↗